Q-linea's directed issue priced at SEK 137 will result in SEK 301m gross of boosted expansion capital and 8,0% of an increased number of shares. The fundraising is executed at a reasonable 5,7% discount to the recent share price. Q-linea's will grow capital to service a rollout powered by the first-class partner, Therma Fisher Scientific. Apart from launch capital, the funds will improve the ASTar automation process further, the US study, and explore Isolates' very substantial market. Initially, we expect the inherent dilution, which is likely to dominate the initial reaction, to balances a moderate share price reaction as the increased potential.